Synageva BioPharma (GEVA)

[rsox]

there is an internet address towards the middle of this page that leads to the guidelines of the dhhs with regards efuzeon

DHHS guidelines - clear recommendations for FUZEON use with
boosted PIs

The importance of FUZEON in the management of HIV has been
recognised by the US Department of Health and Human Services (DHHS).
Their newly updated HIV/AIDS treatment guidelines support the use of
FUZEON with an active boosted PI for the management of treatment
experienced patients. The guidelines state that adding a drug with
activity against drug-resistant virus (e.g. a boosted PI such as
TMC114/r) and a drug with a new mechanism of action (e.g. an HIV
entry inhibitor such as FUZEON) can provide significant
antiretroviral activity.

These data come at a pivotal time as Tibotec has launched this
month an international expanded access programme for TMC114/r. This
will enable patients that are rapidly running out of new treatment
options early access to this investigational agent, which has been
seen to be highly promising when used in combination with FUZEON.

The updated DHHS guidelines (October 6, 2005) are available at
online: http://aidsinfo.nih.gov/guidelines/. <<<<<<<<<<<<<<<<<<<<<

TMC114 is an investigational product

Growing Body of Evidence, RESIST 1&2 / POWER 1&2 / TORO 1&2 -
Collectively the data from all six studies, in over 2,500 patients,
establish a new paradigm in the management of triple
class-experienced patients.